MwanzoADAPY • OTCMKTS
add
Adaptimmune Therapeutics PLC - ADR
Bei iliyotangulia
$ 0.041
Bei za siku
$ 0.035 - $ 0.042
Bei za mwaka
$ 0.020 - $ 0.86
Thamani ya kampuni katika soko
9.58M USD
Wastani wa hisa zilizouzwa
95.52M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
OTCMKTS
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 13.68M | -89.33% |
Matumizi ya uendeshaji wa biashara | 18.48M | -3.13% |
Mapato halisi | -30.34M | -143.64% |
Kiwango cha faida halisi | -221.83 | -509.13% |
Mapato kwa kila hisa | -0.12 | -150.00% |
EBITDA | -27.78M | -138.88% |
Asilimia ya kodi ya mapato | -2.06% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 26.06M | -87.87% |
Jumla ya mali | 130.63M | -59.39% |
Jumla ya dhima | 201.59M | -10.57% |
Jumla ya hisa | -70.96M | — |
hisa zilizosalia | 265.05M | — |
Uwiano wa bei na thamani | -0.15 | — |
Faida inayotokana na mali | -52.45% | — |
Faida inayotokana mtaji | 1,376.60% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -30.34M | -143.64% |
Pesa kutokana na shughuli | -34.78M | -173.38% |
Pesa kutokana na uwekezaji | 18.49M | 2,588.56% |
Pesa kutokana na ufadhili | 1.65M | -93.25% |
Mabadiliko halisi ya pesa taslimu | -15.23M | -121.40% |
Mtiririko huru wa pesa | -23.84M | -135.30% |
Kuhusu
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Tovuti
Wafanyakazi
506
